Invest — Series A Financing | SunRegen Healthcare

Invest in the Future of Neuroprotection

SunRegen is developing the first oral neuroprotective therapy for retinal degeneration: a validated mechanism, an unserved market, and a team with the track record to deliver.

SunRegen Healthcare AG is a clinical-stage Swiss biopharmaceutical company advancing SBC003, the only oral compound with published evidence of protecting neurons against all five major neurotoxic proteins, toward Phase I/II clinical trials in Retinitis Pigmentosa, with a clear platform expansion path into the global neurodegenerative disease market. We are currently building our Series A syndicate of institutional life science investors.

Contact Investor Relations View Pipeline

Total addressable market

Significant

Neurodegenerative therapeutics is a high-growth category (5.7–7.2% CAGR by 2034). Retinal indications are the de-risked entry point to a much larger CNS opportunity.

Unmet patient need

99%

Of RP patients have no approved disease-modifying treatment. All optic atrophy patients lack neuroprotective options.

Capital invested in SBC003

~$6.3M

Deployed across preclinical development, CMC and GLP toxicology studies, and international research collaborations.

Patents granted

8 countries

WO2017211274A1 granted in US, Canada, Japan, China, and 4 additional jurisdictions; 2 applications pending.

Pharma team experience

100+ years

Combined pharmaceutical R&D experience across the scientific team, including 12+ years at Novartis for the CSO.

Series A target

$35M+

To fund IND submission and Phase I/II clinical trials in Retinitis Pigmentosa.

01 / 06

Next: Unmet patient need

By the Numbers

Investment Highlights

Key metrics that define SunRegen's opportunity as a Series A investment.

Click the stack to cycle through every highlight.

Advantage 01

Phenotype-First, De-Risked Discovery

SunRegen observed SBC003's in vivo efficacy first, then reverse-engineered the exact genetic mechanism. This approach — phenotype validated before target selection — substantially reduces the risk of late-stage clinical failure inherent in conventional target-based drug development.

Advantage 02

20+ Models or 5+ Species Validated Efficacy

Highly converging data across four animal models (NMU, rd10, tMCAO, non-human primates), corroborated by in vitro studies in mouse primary neurons and human iPSC-derived neurons, demonstrates SBC003's consistent efficacy. Multi-species convergence is the strongest preclinical predictor of human clinical success.

Advantage 03

Superior Oral Bioavailability

Unlike gene therapies requiring high-risk subretinal injections, or wet AMD biologics requiring monthly intravitreal injections, SBC003 is administered orally. Fast absorption, favorable brain and retinal exposure, and a low molecular weight profile offer a fundamentally superior patient experience and compliance advantage.

Advantage 04

Mutation-Agnostic Mechanism

By targeting the universal downstream apoptotic pathway rather than an upstream genetic mutation, SBC003 is effective across all genetic subtypes of Retinitis Pigmentosa — potentially addressing 100% of the RP patient population rather than the 0.3–1% eligible for current gene therapies such as Luxturna.

Advantage 05

Granted International IP Protection

SunRegen holds granted patents for the SBC003 compound and its therapeutic applications across major global markets including the United States, Canada, Japan, and China, with ongoing international applications securing long-term commercial exclusivity.

Advantage 06

Pedigreed Scientific Leadership

The scientific advisory board, comprising former leaders from Novartis, Allergan, Alcon, and Harvard Medical School, has collectively managed over 40 successful new drug registrations. This track record directly de-risks the preclinical and clinical development pathway for SBC003.

01 / 06

Next: 20+ Models or 5+ Species Validated Efficacy

Why SunRegen

Competitive Advantages

Six structural advantages that compound — from de-risked discovery through granted IP — into a defensible Series A position.

Click the stack to cycle through every advantage.

Investor Relations

We welcome rigorous inquiry from institutional investors and strategic partners interested in SunRegen's Series A financing round.

Contact IR Team Review Publications

SBC003 is investigational and has not been approved by any regulatory authority. This page contains forward-looking statements. Actual results may differ materially. Nothing here constitutes an offer to sell or solicitation to buy securities.